New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 13, 2014
08:04 EDTAGIO, CELGAgios says Celgene exercised option to license AG-221
Agios Pharmaceuticals (AGIO) announced that its partner Celgene (CELG) has exercised its option to an exclusive worldwide license to AG-221, an oral, first-in-class, potent inhibitor of the mutant IDH2 protein. Under the terms of the agreement, the option to license extended to Celgene through the end of Phase 1, but AG-221 has been exercised early based on the Phase 1 data generated to date. AG-221 is currently in a Phase 1 dose escalation study in patients that harbor an IDH2 mutation with advanced hematologic malignancies, including acute myeloid leukemia. Agios and Celgene entered into a global strategic collaboration in April 2010 to develop new therapeutics targeting cancer metabolism. By exercising its exclusive option under the terms of the agreement, Celgene gains worldwide development and commercialization rights for AG-221. Agios, in addition to contributing its scientific and translational expertise, will continue to conduct early clinical development and regulatory activities within the AG-221 development program in collaboration with Celgene. Celgene is responsible for all development costs for AG-221. Agios is eligible for up to $120 million in milestone payments and a tiered royalty on any net sales. Agios also has the right to conduct a portion of any commercialization activities for AG-221 in the United States. AG-221 is part of Agiosí IDH portfolio that also includes the IDH1 mutant inhibitor AG-120, which the company continues to develop and is in Phase 1 clinical trials in advanced solid tumors and hematologic malignancies. Agios retains U.S. rights to the IDH1 program, and Celgene has an exclusive option to ex-U.S. rights for the program. Agios continues to advance its discovery and research of cancer metabolism targets.
News For AGIO;CELG From The Last 14 Days
Check below for free stories on AGIO;CELG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 22, 2014
11:56 EDTAGIOAgios Pharmaceuticals management to meet with Leerink
Subscribe for More Information
07:21 EDTCELGEBD Group to hold a conference
Subscribe for More Information
September 17, 2014
07:00 EDTCELGConcert Pharmaceuticals announces initiation of CTP-730 Phase 1 trial
Subscribe for More Information
September 15, 2014
07:27 EDTCELGIBC Life Sciences to hold a conference
Subscribe for More Information
September 11, 2014
16:16 EDTAGIOBB Biotech reports 5.1% passive stake in Agios Pharmaceuticals
Subscribe for More Information
September 9, 2014
07:51 EDTCELGNICE says Abraxane price not justified by limited benefit in pancreatic cancer
Subscribe for More Information
September 8, 2014
07:26 EDTCELGMorgan Stanley to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use